TrialThe oncologist2023

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.

Shannon Stockton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.